August 28th 2025
The authors examine common FDA 483 findings and outline strategies to address and prevent regulatory non-compliance.
Evaluating Impurities in Drugs (Part III of III)
April 2nd 2012In Part III of a three-part article, the authors examine various degradation routes of APIs, impurities arising from interactions in formulations, metabolite impurities, various analytical methods to measure impuritie, and ways to control impurities.